Terms: = Thyroid cancer AND STRN, ENSG00000115808, 6801, O43815, SG2NA, MGC125642
15 results:
1. Molecular Genetics of Diffuse Sclerosing Papillary thyroid cancer.
Alswailem M; Alghamdi B; Alotaibi A; Aljomiah A; Al-Hindi H; Murugan AK; Abouelhoda M; Shi Y; Alzahrani AS
J Clin Endocrinol Metab; 2023 Aug; 108(9):e704-e711. PubMed ID: 36995892
[TBL] [Abstract] [Full Text] [Related]
2. Inhibition of ALK-Signaling Overcomes strn-ALK-Induced Downregulation of the Sodium Iodine Symporter and Restores Radioiodine Uptake in thyroid Cells.
Nikitski AV; Condello V; Divakaran SS; Nikiforov YE
Thyroid; 2023 Apr; 33(4):464-473. PubMed ID: 36585857
[No Abstract] [Full Text] [Related]
3. Mutational analysis using next generation sequencing in pediatric thyroid cancer reveals BRAF and fusion oncogenes are common.
Newfield RS; Jiang W; Sugganth DX; Hantash FM; Lee E; Newbury RO
Int J Pediatr Otorhinolaryngol; 2022 Jun; 157():111121. PubMed ID: 35397361
[TBL] [Abstract] [Full Text] [Related]
4. Diverse Oncogenic Fusions and Distinct Gene Expression Patterns Define the Genomic Landscape of Pediatric Papillary thyroid Carcinoma.
Stosic A; Fuligni F; Anderson ND; Davidson S; de Borja R; Acker M; Forte V; Campisi P; Propst EJ; Wolter NE; Chami R; Mete O; Malkin D; Shlien A; Wasserman JD
Cancer Res; 2021 Nov; 81(22):5625-5637. PubMed ID: 34535459
[TBL] [Abstract] [Full Text] [Related]
5. Detection of strn-ALK fusion in thyroid nodules with indeterminate cytopathology facilitates papillary thyroid cancer diagnosis.
Jurkiewicz M; Cimic A; Murty VV; Kuo JH; Hsiao S; Fazlollahi L; Fernandes H
Diagn Cytopathol; 2021 Apr; 49(4):E146-E151. PubMed ID: 33085842
[TBL] [Abstract] [Full Text] [Related]
6. The Clinicopathological Results of thyroid cancer With BRAFV600E Mutation in the Young Population of Fukushima.
Iwadate M; Mitsutake N; Matsuse M; Fukushima T; Suzuki S; Matsumoto Y; Ookouchi C; Mizunuma H; Nakamura I; Nakano K; Sakamoto A; Hirokawa M; Ito M; Naganuma H; Hashimoto Y; Shimura H; Yamashita S; Suzuki S
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32827026
[TBL] [Abstract] [Full Text] [Related]
7. Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization.
Chu YH; Wirth LJ; Farahani AA; Nosé V; Faquin WC; Dias-Santagata D; Sadow PM
Mod Pathol; 2020 Dec; 33(12):2458-2472. PubMed ID: 32737449
[TBL] [Abstract] [Full Text] [Related]
8. Characterization of thyroid cancer driven by known and novel ALK fusions.
Panebianco F; Nikitski AV; Nikiforova MN; Kaya C; Yip L; Condello V; Wald AI; Nikiforov YE; Chiosea SI
Endocr Relat Cancer; 2019 Nov; 26(11):803-814. PubMed ID: 31539879
[TBL] [Abstract] [Full Text] [Related]
9. Anaplastic lymphoma kinase (ALK) gene rearrangements in radiation-related human papillary thyroid carcinoma after the Chernobyl accident.
Arndt A; Steinestel K; Rump A; Sroya M; Bogdanova T; Kovgan L; Port M; Abend M; Eder S
J Pathol Clin Res; 2018 Jul; 4(3):175-183. PubMed ID: 29633575
[TBL] [Abstract] [Full Text] [Related]
10. Investigation of the Relationship Between Radiation Dose and Gene Mutations and Fusions in Post-Chernobyl thyroid cancer.
Efanov AA; Brenner AV; Bogdanova TI; Kelly LM; Liu P; Little MP; Wald AI; Hatch M; Zurnadzy LY; Nikiforova MN; Drozdovitch V; Leeman-Neill R; Mabuchi K; Tronko MD; Chanock SJ; Nikiforov YE
J Natl Cancer Inst; 2018 Apr; 110(4):371-378. PubMed ID: 29165687
[TBL] [Abstract] [Full Text] [Related]
11.
Bastos AU; de Jesus AC; Cerutti JM
Eur J Endocrinol; 2018 Jan; 178(1):83-91. PubMed ID: 29046324
[TBL] [Abstract] [Full Text] [Related]
12. Identification of Three Novel Fusion Oncogenes, SQSTM1/NTRK3, AFAP1L2/RET, and PPFIBP2/RET, in thyroid cancers of Young Patients in Fukushima.
Iyama K; Matsuse M; Mitsutake N; Rogounovitch T; Saenko V; Suzuki K; Ashizawa M; Ookouchi C; Suzuki S; Mizunuma H; Fukushima T; Suzuki S; Yamashita S
Thyroid; 2017 Jun; 27(6):811-818. PubMed ID: 28351223
[TBL] [Abstract] [Full Text] [Related]
13. Standard immunohistochemistry efficiently screens for anaplastic lymphoma kinase rearrangements in differentiated thyroid cancer.
Park G; Kim TH; Lee HO; Lim JA; Won JK; Min HS; Lee KE; Park DJ; Park YJ; Park WY
Endocr Relat Cancer; 2015 Feb; 22(1):55-63. PubMed ID: 25527510
[TBL] [Abstract] [Full Text] [Related]
14. Identification of the transforming strn-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer.
Kelly LM; Barila G; Liu P; Evdokimova VN; Trivedi S; Panebianco F; Gandhi M; Carty SE; Hodak SP; Luo J; Dacic S; Yu YP; Nikiforova MN; Ferris RL; Altschuler DL; Nikiforov YE
Proc Natl Acad Sci U S A; 2014 Mar; 111(11):4233-8. PubMed ID: 24613930
[TBL] [Abstract] [Full Text] [Related]
15. Identification of a recurrent strn/ALK fusion in thyroid carcinomas.
Pérot G; Soubeyran I; Ribeiro A; Bonhomme B; Savagner F; Boutet-Bouzamondo N; Hostein I; Bonichon F; Godbert Y; Chibon F
PLoS One; 2014; 9(1):e87170. PubMed ID: 24475247
[TBL] [Abstract] [Full Text] [Related]
